JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase 3 Study of Rosuvastatin (CRESTOR®) 20 mg in the Prevention of Cardiovascular Events Among Subjects With Low Levels of Low Density Lipoprotein(LDL) Cholesterol & Elevated Levels of C-Reactive Protein
Sponsor: AstraZeneca
Listed as NCT00239681, this PHASE3 trial focuses on Elevated High-sensitivity C-Reactive Protein (hsCRP) and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 10 times since 2003, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Terminated PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Terminated PHASE3
-
Nov 2025 — Feb 2026 [monthly]
Terminated PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Feb 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aguas Buenas, Puerto Rico, Aguascalientes, Mexico, Airdrie, United Kingdom, Akron, United States, Albany, United States, Albuquerque, United States, Aleksandrów Łódzki, Poland, Alexandria, United States, Alhambra, United States, Alkmaar, Netherlands and 810 more location s